Published in Mol Psychiatry on December 15, 2009
A resource of Cre driver lines for genetic targeting of GABAergic neurons in cerebral cortex. Neuron (2011) 6.93
Why primate models matter. Am J Primatol (2014) 2.05
The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry (2010) 1.80
CRHR1 genotypes, neural circuits and the diathesis for anxiety and depression. Mol Psychiatry (2012) 1.42
The dappled nature of causes of psychiatric illness: replacing the organic-functional/hardware-software dichotomy with empirically based pluralism. Mol Psychiatry (2012) 1.35
Stress and visceral pain: from animal models to clinical therapies. Exp Neurol (2011) 1.25
The three-hit concept of vulnerability and resilience: toward understanding adaptation to early-life adversity outcome. Psychoneuroendocrinology (2013) 1.22
Understanding resilience. Front Behav Neurosci (2013) 1.19
An affective disorder in zebrafish with mutation of the glucocorticoid receptor. Mol Psychiatry (2012) 1.18
Corticotropin releasing factor signaling in colon and ileum: regulation by stress and pathophysiological implications. J Physiol Pharmacol (2009) 1.13
Corticotropin-releasing hormone receptor type 1 (CRHR1) genetic variation and stress interact to influence reward learning. J Neurosci (2011) 1.10
Therapeutic utility of non-peptidic CRF1 receptor antagonists in anxiety, depression, and stress-related disorders: evidence from animal models. Pharmacol Ther (2010) 1.06
Convergent functional genomics of anxiety disorders: translational identification of genes, biomarkers, pathways and mechanisms. Transl Psychiatry (2011) 1.06
Role of vascular endothelial growth factor in adult hippocampal neurogenesis: implications for the pathophysiology and treatment of depression. Behav Brain Res (2011) 1.01
Neurogenetics of depression: a focus on reward processing and stress sensitivity. Neurobiol Dis (2012) 1.00
Abnormal error processing in depressive states: a translational examination in humans and rats. Transl Psychiatry (2015) 0.93
Common inversion polymorphism at 17q21.31 affects expression of multiple genes in tissue-specific manner. BMC Genomics (2012) 0.91
Neurosteroid, GABAergic and hypothalamic pituitary adrenal (HPA) axis regulation: what is the current state of knowledge in humans? Psychopharmacology (Berl) (2014) 0.89
Metabolite profiling of antidepressant drug action reveals novel drug targets beyond monoamine elevation. Transl Psychiatry (2011) 0.88
Corticotropin-releasing factor-related peptides, serotonergic systems, and emotional behavior. Front Neurosci (2013) 0.88
Enduring sensorimotor gating abnormalities following predator exposure or corticotropin-releasing factor in rats: a model for PTSD-like information-processing deficits? Neuropharmacology (2011) 0.88
Mineralocorticoid receptor stimulation improves cognitive function and decreases cortisol secretion in depressed patients and healthy individuals. Neuropsychopharmacology (2014) 0.86
Family-based study of AVPR1B association and interaction with stressful life events on depression and anxiety in suicide attempts. Neuropsychopharmacology (2013) 0.86
Ambulatory and challenge-associated heart rate variability measures predict cardiac responses to real-world acute emotional stress. Biol Psychiatry (2010) 0.84
Genetic Moderation of Stress Effects on Corticolimbic Circuitry. Neuropsychopharmacology (2015) 0.84
The cortisol awakening response and major depression: examining the evidence. Neuropsychiatr Dis Treat (2015) 0.83
Ethanol concentration-dependent effects and the role of stress on ethanol drinking in corticotropin-releasing factor type 1 and double type 1 and 2 receptor knockout mice. Psychopharmacology (Berl) (2011) 0.82
An integrated map of corticotropin-releasing hormone signaling pathway. J Cell Commun Signal (2013) 0.82
Regulation of AMPA receptor surface trafficking and synaptic plasticity by a cognitive enhancer and antidepressant molecule. Mol Psychiatry (2012) 0.81
Variable telomere length across post-mortem human brain regions and specific reduction in the hippocampus of major depressive disorder. Transl Psychiatry (2015) 0.81
Using animal models to study post-partum psychiatric disorders. Br J Pharmacol (2014) 0.81
Sustained AAV-mediated overexpression of CRF in the central amygdala diminishes the depressive-like state associated with nicotine withdrawal. Transl Psychiatry (2014) 0.80
Human fear acquisition deficits in relation to genetic variants of the corticotropin releasing hormone receptor 1 and the serotonin transporter. PLoS One (2013) 0.80
Inhibition of corticotropin releasing factor expression in the central nucleus of the amygdala attenuates stress-induced behavioral and endocrine responses. Front Neurosci (2013) 0.80
Requirement of phospholipase C and protein kinase C in cholecystokinin-mediated facilitation of NMDA channel function and anxiety-like behavior. Hippocampus (2011) 0.79
Medial prefrontal cortex: genes linked to bipolar disorder and schizophrenia have altered expression in the highly social maternal phenotype. Front Behav Neurosci (2014) 0.79
Overexpressing Corticotropin-Releasing Factor in the Primate Amygdala Increases Anxious Temperament and Alters Its Neural Circuit. Biol Psychiatry (2016) 0.78
MicroRNA-326 acts as a molecular switch in the regulation of midbrain urocortin 1 expression. J Psychiatry Neurosci (2016) 0.77
Attenuated Levels of Hippocampal Connexin 43 and its Phosphorylation Correlate with Antidepressant- and Anxiolytic-Like Activities in Mice. Front Cell Neurosci (2015) 0.77
Enhanced upregulation of CRH mRNA expression in the nucleus accumbens of male rats after a second injection of methamphetamine given thirty days later. PLoS One (2014) 0.77
Lifelong CRF overproduction is associated with altered gene expression and sensitivity of discrete GABA(A) and mGlu receptor subtypes. Psychopharmacology (Berl) (2011) 0.77
Evidence for the role of corticotropin-releasing factor in major depressive disorder. Neurosci Biobehav Rev (2015) 0.77
Psychiatric symptoms in adolescents: FKBP5 genotype-early life adversity interaction effects. Eur Child Adolesc Psychiatry (2015) 0.76
Altered relaxin family receptors RXFP1 and RXFP3 in the neocortex of depressed Alzheimer's disease patients. Psychopharmacology (Berl) (2015) 0.76
CRHBP polymorphisms predict chronic pain development following motor vehicle collision. Pain (2016) 0.76
An active inference theory of allostasis and interoception in depression. Philos Trans R Soc Lond B Biol Sci (2016) 0.76
Family Economic Hardship, Corticotropin-Releasing Hormone Receptor Polymorphisms, and Depressive Symptoms in Rural African-American Youths. J Adolesc Health (2015) 0.76
Epidemiological support for genetic variability at hypothalamic-pituitary-adrenal axis and serotonergic system as risk factors for major depression. Neuropsychiatr Dis Treat (2015) 0.76
Genetic variants in the genes of the stress hormone signalling pathway and depressive symptoms during and after pregnancy. Biomed Res Int (2014) 0.76
Re-defininG AddiC(CH3)Tion: genomics and epigenomics on substance use disorders. Mol Genet Genomic Med (2014) 0.75
Human amygdala engagement moderated by early life stress exposure is a biobehavioral target for predicting recovery on antidepressants. Proc Natl Acad Sci U S A (2016) 0.75
Forecasting aggression: toward a new interdisciplinary understanding of what makes some troubled youth turn violent. Cerebrum (2011) 0.75
The Antidepressant Effect of L-Tyrosine-Loaded Nanoparticles: Behavioral Aspects. Ann Neurosci (2016) 0.75
The relationship between alcohol consumption, perceived stress, and CRHR1 genotype on the hypothalamic-pituitary-adrenal axis in rural African Americans. Front Psychol (2015) 0.75
Short- and long-term effects of stress during adolescence on emotionality and HPA function of animals exposed to alcohol prenatally. Psychoneuroendocrinology (2016) 0.75
Brainstem neuronal and behavioral activation by corticotropin-releasing hormone depend on the behavioral state of the animal. Horm Behav (2011) 0.75
The CRF System as a Therapeutic Target for Neuropsychiatric Disorders. Trends Pharmacol Sci (2016) 0.75
Perturbations in Effort-Related Decision-Making Driven by Acute Stress and Corticotropin-Releasing Factor. Neuropsychopharmacology (2016) 0.75
Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder. Biol Psychiatry (2017) 0.75
From Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder. Front Cell Neurosci (2017) 0.75
HPA Axis Genes, and their Interaction with Childhood Maltreatment, are Related to Cortisol Levels and Stress-Related Phenotypes. Neuropsychopharmacology (2017) 0.75
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature (2007) 144.95
The sequence of the human genome. Science (2001) 101.55
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
The International HapMap Project. Nature (2003) 73.65
The future of genetic studies of complex human diseases. Science (1996) 64.76
A common inversion under selection in Europeans. Nat Genet (2005) 13.66
Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet (2008) 10.49
Discovery of previously unidentified genomic disorders from the duplication architecture of the human genome. Nat Genet (2006) 10.36
Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science (1981) 9.64
Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry (2000) 9.02
Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA (2000) 7.21
Whole-genome association study of bipolar disorder. Mol Psychiatry (2008) 6.80
A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry (2007) 6.72
The essence of SNPs. Gene (1999) 6.44
A new chromosome 17q21.31 microdeletion syndrome associated with a common inversion polymorphism. Nat Genet (2006) 5.92
Microdeletion encompassing MAPT at chromosome 17q21.3 is associated with developmental delay and learning disability. Nat Genet (2006) 5.59
Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet (2008) 4.71
Influence of child abuse on adult depression: moderation by the corticotropin-releasing hormone receptor gene. Arch Gen Psychiatry (2008) 4.65
Relationship between multiple forms of childhood maltreatment and adult mental health in community respondents: results from the adverse childhood experiences study. Am J Psychiatry (2003) 4.59
A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry (2001) 4.55
Altered pituitary-adrenal axis responses to provocative challenge tests in adult survivors of childhood abuse. Am J Psychiatry (2001) 4.36
Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature (1995) 4.24
Early, postnatal experience alters hypothalamic corticotropin-releasing factor (CRF) mRNA, median eminence CRF content and stress-induced release in adult rats. Brain Res Mol Brain Res (1993) 4.13
Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet (2004) 3.91
Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. Mol Psychiatry (2008) 3.85
Sex-specific programming of offspring emotionality after stress early in pregnancy. J Neurosci (2008) 3.72
Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts. Mol Psychiatry (2008) 3.68
The genetics of depression: a review. Biol Psychiatry (2005) 3.35
Combined analysis from eleven linkage studies of bipolar disorder provides strong evidence of susceptibility loci on chromosomes 6q and 8q. Am J Hum Genet (2005) 3.24
Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci U S A (2001) 3.23
A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci (2007) 3.16
The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol (1999) 3.10
A Swedish national twin study of lifetime major depression. Am J Psychiatry (2006) 3.06
Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet (2000) 3.04
Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression. J Neurosci (1995) 3.04
Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: Bipolar disorder. Am J Hum Genet (2003) 3.02
The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology (2009) 3.01
Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci U S A (2001) 2.87
Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Brain Res Rev (1991) 2.85
Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science (1984) 2.83
Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci (2003) 2.79
Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci U S A (1995) 2.70
Long-term behavioral and neuroendocrine adaptations to adverse early experience. Prog Brain Res (2000) 2.45
Interaction of childhood maltreatment with the corticotropin-releasing hormone receptor gene: effects on hypothalamic-pituitary-adrenal axis reactivity. Biol Psychiatry (2009) 2.44
Long-term consequences of neonatal rearing on central corticotropin-releasing factor systems in adult male rat offspring. Neuropsychopharmacology (2005) 2.35
Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders. Proc Natl Acad Sci U S A (1996) 2.30
Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor-2. Nat Genet (2000) 2.24
Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry (1997) 2.22
Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc Natl Acad Sci U S A (1994) 2.14
Protective effect of CRHR1 gene variants on the development of adult depression following childhood maltreatment: replication and extension. Arch Gen Psychiatry (2009) 2.01
Neurobiological consequences of childhood trauma. J Clin Psychiatry (2004) 2.00
Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr Opin Pharmacol (2002) 1.97
Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol Disord Drug Targets (2006) 1.97
Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am J Psychiatry (1999) 1.96
The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol Psychiatry (1996) 1.95
Corticotropin-releasing factor in brain: a role in activation, arousal, and affect regulation. J Pharmacol Exp Ther (2004) 1.92
Two variants in Ankyrin 3 (ANK3) are independent genetic risk factors for bipolar disorder. Mol Psychiatry (2008) 1.92
Deletion of crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor-2. Nat Genet (2000) 1.90
Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res (2000) 1.89
The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry (2005) 1.81
Childhood parental loss and adult hypothalamic-pituitary-adrenal function. Biol Psychiatry (2008) 1.80
International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev (2003) 1.79
Genotyping technologies for genetic research. Annu Rev Genomics Hum Genet (2009) 1.78
Interaction between CRHR1 gene and stressful life events predicts adolescent heavy alcohol use. Biol Psychiatry (2007) 1.78
The dexamethasone/corticotropin-releasing factor test in men with major depression: role of childhood trauma. Biol Psychiatry (2007) 1.71
Alterations in diurnal cortisol rhythm and acoustic startle response in nonhuman primates with adverse rearing. Biol Psychiatry (2005) 1.65
A genome survey indicates a possible susceptibility locus for bipolar disorder on chromosome 22. Proc Natl Acad Sci U S A (2001) 1.64
Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J Comp Neurol (1999) 1.63
Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci (2004) 1.62
The central distribution of a corticotropin-releasing factor (CRF)-binding protein predicts multiple sites and modes of interaction with CRF. Proc Natl Acad Sci U S A (1992) 1.60
Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology (1994) 1.60
Alternative splicing of CRH-R1 receptors in human and mouse skin: identification of new variants and their differential expression. FASEB J (2001) 1.59
Urocortin expression in rat brain: evidence against a pervasive relationship of urocortin-containing projections with targets bearing type 2 CRF receptors. J Comp Neurol (1999) 1.57
Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty. Life Sci (1982) 1.57
Allostasis and dysregulation of corticotropin-releasing factor and neuropeptide Y systems: implications for the development of alcoholism. Pharmacol Biochem Behav (2004) 1.56
Corticotropin-releasing factor activates noradrenergic neurons of the locus coeruleus. Brain Res (1983) 1.54
Reduced corticotropin releasing factor binding sites in the frontal cortex of suicide victims. Arch Gen Psychiatry (1988) 1.53
Induction of corticotropin-releasing hormone gene expression by glucocorticoids: implication for understanding the states of fear and anxiety and allostatic load. Psychoneuroendocrinology (1998) 1.52
Cloning and characterization of the cDNAs for human and rat corticotropin releasing factor-binding proteins. Nature (1991) 1.51
Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol Metab (2002) 1.46
Association of corticotropin-releasing hormone receptor1 gene SNP and haplotype with major depression. Neurosci Lett (2006) 1.45
Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. Horm Behav (2006) 1.43
Polymorphisms in CRHR1 and the serotonin transporter loci: gene x gene x environment interactions on depressive symptoms. Am J Med Genet B Neuropsychiatr Genet (2010) 1.42
Cerebrospinal fluid corticotropin-releasing factor and perceived early-life stress in depressed patients and healthy control subjects. Neuropsychopharmacology (2004) 1.41
Effect of Childhood Trauma on Adult Depression and Neuroendocrine Function: Sex-Specific Moderation by CRH Receptor 1 Gene. Front Behav Neurosci (2009) 1.41
The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. J Neurosci (2006) 1.40
The early life environment and the epigenome. Biochim Biophys Acta (2009) 1.39
Corticotropin-releasing factor in posttraumatic stress disorder (PTSD) with secondary psychotic symptoms, nonpsychotic PTSD, and healthy control subjects. Biol Psychiatry (2003) 1.37
Increased anxiety-like behavior and ethanol self-administration in dependent rats: reversal via corticotropin-releasing factor-2 receptor activation. Alcohol Clin Exp Res (2004) 1.36
Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Mol Psychiatry (2004) 1.36
Phenotypic expansion and further characterisation of the 17q21.31 microdeletion syndrome. J Med Genet (2009) 1.28
Corticosteroid receptor polymorphisms: determinants of vulnerability and resilience. Eur J Pharmacol (2008) 1.26
Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatry (1993) 1.25
Twin studies of psychiatric illness. Current status and future directions. Arch Gen Psychiatry (1993) 1.25
Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. Am J Med Genet C Semin Med Genet (2008) 1.24
Molecular and functional characterization of novel CRFR1 isoforms from the skin. Eur J Biochem (2004) 1.22
A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am J Psychiatry (2008) 1.19
Evidence for a putative bipolar disorder locus on 2p13-16 and other potential loci on 4q31, 7q34, 8q13, 9q31, 10q21-24, 13q32, 14q21 and 17q11-12. Mol Psychiatry (2003) 1.19
Continuous expression of corticotropin-releasing factor in the central nucleus of the amygdala emulates the dysregulation of the stress and reproductive axes. Mol Psychiatry (2008) 1.18
A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med (2000) 10.25
The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies. Biol Psychiatry (2001) 7.80
Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA (2000) 7.21
The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry (1998) 4.83
Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med (2001) 4.39
Altered pituitary-adrenal axis responses to provocative challenge tests in adult survivors of childhood abuse. Am J Psychiatry (2001) 4.36
The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol (1999) 3.10
Physiology and pharmacology of corticotropin-releasing factor. Pharmacol Rev (1991) 3.07
Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety. Mol Psychiatry (2009) 2.94
Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science (1984) 2.83
Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem (1994) 2.77
Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety (2000) 2.76
Long-term behavioral and neuroendocrine adaptations to adverse early experience. Prog Brain Res (2000) 2.45
Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders. Proc Natl Acad Sci U S A (1996) 2.30
Effects of early adverse experiences on brain structure and function: clinical implications. Biol Psychiatry (2000) 2.27
Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry (1997) 2.22
Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther (1997) 2.16
Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry (2001) 2.08
Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry (2001) 2.05
Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry (1998) 2.03
Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. Psychiatr Clin North Am (1998) 1.85
Lower CSF oxytocin concentrations in women with a history of childhood abuse. Mol Psychiatry (2008) 1.82
Exaggerated platelet reactivity in major depression. Am J Psychiatry (1996) 1.72
Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry (1995) 1.72
Sertraline and desmethylsertraline in human breast milk and nursing infants. Am J Psychiatry (1997) 1.62
Apolipoprotein E-epsilon 4 frequency in geriatric depression. Biol Psychiatry (1996) 1.56
"Normal pressure" pseudotumor cerebri. J Neuroophthalmol (1996) 1.55
The impact of early adverse experiences on brain systems involved in the pathophysiology of anxiety and affective disorders. Biol Psychiatry (1999) 1.52
Hypercortisolemia and hippocampal changes in depression. Psychiatry Res (1993) 1.52
Effects of sodium valproate on corticotropin-releasing factor systems in rat brain. Neuropsychopharmacology (2001) 1.51
Long-term behavioral effects of repetitive pain in neonatal rat pups. Physiol Behav (1999) 1.51
Paroxetine binding to the rat norepinephrine transporter in vivo. Biol Psychiatry (2000) 1.49
Persistent changes in corticotropin-releasing factor neuronal systems induced by maternal deprivation. Endocrinology (1996) 1.48
Magnetic resonance imaging of the caudate nuclei in depression. Preliminary observations. Arch Gen Psychiatry (1992) 1.41
Neurotensin and dopamine interactions. Pharmacol Rev (2001) 1.35
Role of norepinephrine in the pathophysiology and treatment of mood disorders. Biol Psychiatry (1999) 1.35
The role of early adverse life events in the etiology of depression and posttraumatic stress disorder. Focus on corticotropin-releasing factor. Ann N Y Acad Sci (1997) 1.32
Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress. J Neurosci (1986) 1.30
Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin. Nature (1976) 1.29
A magnetic resonance imaging study of putamen nuclei in major depression. Psychiatry Res (1991) 1.26
Neurobiology of posttraumatic stress disorder. Curr Opin Neurobiol (2000) 1.20
Neurobiological effects of childhood abuse: implications for the pathophysiology of depression and anxiety. Arch Womens Ment Health (2003) 1.20
Hippocampal abnormalities in depression. J Neuropsychiatry Clin Neurosci (1991) 1.19
Corticotropin-releasing factor produces fear-enhancing and behavioral activating effects following infusion into the locus coeruleus. J Neurosci (1990) 1.18
Persistent changes in corticotropin-releasing factor systems due to early life stress: relationship to the pathophysiology of major depression and post-traumatic stress disorder. Psychopharmacol Bull (1997) 1.18
Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet (2001) 1.18
Continuous expression of corticotropin-releasing factor in the central nucleus of the amygdala emulates the dysregulation of the stress and reproductive axes. Mol Psychiatry (2008) 1.18
Assessment and treatment of depression in the cancer patient. J Psychosom Res (1998) 1.17
Pituitary size in depression. J Clin Endocrinol Metab (1991) 1.16
Women at risk for postpartum-onset major depression. Am J Obstet Gynecol (1995) 1.15
Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry (2000) 1.12
The role of corticotropin-releasing factor in the pathophysiology of affective and anxiety disorders: laboratory and clinical studies. Ciba Found Symp (1993) 1.11
CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Am J Psychiatry (1997) 1.10
Differential functional connectivity within an emotion regulation neural network among individuals resilient and susceptible to the depressogenic effects of early life stress. Psychol Med (2012) 1.08
Depression during pregnancy and the puerperium. J Clin Psychiatry (1997) 1.07
Contemporary management of depression. Am J Med (1994) 1.07
Increased corticotropin-releasing factor concentrations in the bed nucleus of the stria terminalis of anhedonic rats. Eur J Pharmacol (2000) 1.07
Corticotropin releasing factor (CRF): studies in alcohol preferring and non-preferring rats. Psychopharmacology (Berl) (1992) 1.04
Variable foraging demand rearing: sustained elevations in cisternal cerebrospinal fluid corticotropin-releasing factor concentrations in adult primates. Biol Psychiatry (2001) 1.03
Neurotensin blocks certain amphetamine-induced behaviours. Nature (1981) 1.02
Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group. Am J Geriatr Psychiatry (1997) 1.02
Depression and anxiety: role of the locus coeruleus and corticotropin-releasing factor. Brain Res Bull (1994) 1.02
Neurotensin: perchance an endogenous neuroleptic? Biol Psychiatry (1980) 1.01
Overexpression of the high affinity choline transporter in cortical regions affected by Alzheimer's disease. Evidence from rapid autopsy studies. J Clin Invest (1994) 1.01
Elevated CSF CRF in suicide victims. Biol Psychiatry (1989) 1.01
Subcortical hyperintensities on brain magnetic resonance imaging: a comparison between late age onset and early onset elderly depressed subjects. Neurobiol Aging (1991) 1.01
Neurotensin: central nervous system effects of a hypothalamic peptide. Brain Res (1977) 1.01
Cerebrospinal fluid concentrations of somatostatin and biogenic amines in grown primates reared by mothers exposed to manipulated foraging conditions. Arch Gen Psychiatry (1998) 1.01
The corticotropin-releasing hormone test in patients with posttraumatic stress disorder. Biol Psychiatry (1989) 1.01
CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am J Psychiatry (1987) 1.01
Subclinical hypothyroidism: a review of neuropsychiatric aspects. Int J Psychiatry Med (1990) 1.00
Depression and endocrine disorders: focus on the thyroid and adrenal system. Br J Psychiatry Suppl (1996) 0.99
Leukoencephalopathy in patients diagnosed as major depressive. Biol Psychiatry (1988) 0.99
Postnatal development of regional binding of corticotropin-releasing factor and adenylate cyclase activity in the rat brain. Prog Neuropsychopharmacol Biol Psychiatry (1992) 0.99
Chronic administration of the triazolobenzodiazepine alprazolam produces opposite effects on corticotropin-releasing factor and urocortin neuronal systems. J Neurosci (2000) 0.99
Neurotensin, a biologically active peptide. Life Sci (1978) 0.99
Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. Am J Psychiatry (1991) 0.98
Alterations in nociception and body temperature after intracisternal administration of neurotensin, beta-endorphin, other endogenous peptides, and morphine. Proc Natl Acad Sci U S A (1979) 0.98
Maternal separation in neonatal rats elicits activation of the hypothalamic-pituitary-adrenocortical axis: a putative role for corticotropin-releasing factor. Psychoneuroendocrinology (1993) 0.98
Problems with currently available antidepressants. J Clin Psychiatry (2000) 0.97
Synthesis and characterization of fluorinated and iodinated pyrrolopyrimidines as PET/SPECT ligands for the CRF1 receptor. Nucl Med Biol (2001) 0.96
Paroxetine in human breast milk and nursing infants. Am J Psychiatry (2000) 0.96
Behavioral and neurochemical effects of neurotensin microinjection into the ventral tegmental area of the rat. Neuroscience (1983) 0.96
Impact of physical illness on quality of life and antidepressant response in geriatric major depression. Fluoxetine Collaborative Study Group. J Am Geriatr Soc (1996) 0.95
The effects of alprazolam on corticotropin-releasing factor neurons in the rat brain: acute time course, chronic treatment and abrupt withdrawal. J Pharmacol Exp Ther (1991) 0.95
The effect of neurotensin on food consumption in the rat. Eur J Pharmacol (1982) 0.95
Altered pituitary hormone response to naloxone in hypertension development. Hypertension (1989) 0.94
The serotonin transporter and depression. Depress Anxiety (1998) 0.94
Depression in women treated for gynecological cancer: clinical and neuroendocrine assessment. Am J Psychiatry (1986) 0.94
The neurobiology of neurotensin: focus on neurotensin-dopamine interactions. Regul Pept (1991) 0.94
Corticotropin-releasing factor (CRF), CRF-binding protein (CRF-BP), and CRF/CRF-BP complex in Alzheimer's disease and control postmortem human brain. J Neurochem (1997) 0.94
5 alpha-pregnane-3 alpha, 21-diol-20-one (THDOC) attenuates mild stress-induced increases in plasma corticosterone via a non-glucocorticoid mechanism: comparison with alprazolam. Brain Res (1992) 0.93
Novel treatments of schizophrenia: targeting the neurotensin system. CNS Neurol Disord Drug Targets (2006) 0.93
The neurobiology of urocortin. Regul Pept (2000) 0.93
Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing. Neuroscience (1984) 0.92
Models of neuroendocrine regulation: use of monosodium glutamate as an investigational tool. Dev Neurosci (1978) 0.92
Antithyroid antibodies in depressed patients. Am J Psychiatry (1985) 0.92
Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment. Am J Psychiatry (1982) 0.92
CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates. Schizophr Res (1994) 0.92
Neurochemical correlates of sympathetic activation during severe alcohol withdrawal. Alcohol Clin Exp Res (1994) 0.92